Special section on drug metabolism and the microbiome - Minireview: Investigation of host-gut microbiota modulation of therapeutic outcome

Drug Metabolism and Disposition

Volumn 43, Issue 10, 2015, Pages 1619-1631

  Yip, Lian Yee ^a,b   Chan, Eric Chun Yong ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN; DRUG;

ARTICLE; CARDIOVASCULAR RISK; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TRANSFORMATION; ENTEROHEPATIC CIRCULATION; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE FLORA; LIVER METABOLISM; METABOLIC PARAMETERS; METABONOMICS; METAGENOMICS; NONHUMAN; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME; XENOBIOTIC METABOLISM; ANIMAL; DRUG EFFECTS; GASTROINTESTINAL ABSORPTION; LIVER; METABOLISM; METABOLOMICS; PHYSIOLOGY; PROCEDURES;

ANIMALS; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER; METABOLOMICS; PHARMACEUTICAL PREPARATIONS; TREATMENT OUTCOME;

EID: 84946207422     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.063750     Document Type: Article

References (181)

1. Aa J, Shao F, Wang G, Huang Q, Zha W, Yan B, Zheng T, Liu L, Cao B, and Shi J, et al. (2011) Gas chromatography time-of-flight mass spectrometry based metabolomic approach to evaluating toxicity of triptolide. Metabolomics 7:217-225.
2. Abushamat M (1993) The role of gastrointestinal microflora in the metabolism of drugs. Int J Pharm 97: 1-13.
3. Acinas SG, Sarma-Rupavtarm R, Klepac-Ceraj V, and Polz MF (2005) PCR-induced sequence artifacts and bias: insights from comparison of two 16S rRNA clone libraries constructed from the same sample. Appl Environ Microbiol 71:8966-8969.
4. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, and Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6926.
5. Arteaga S, Andrade-Cetto A, and Cárdenas R (2005) Larrea tridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. J Ethnopharmacol 98:231-239.
6. Basit AW and Lacey LF (2001) Colonic metabolism of ranitidine: implications for its delivery and absorption. Int J Pharm 227:157-165.
7. Basit AW, Newton JM, and Lacey LF (2002) Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm 237:23-33.
8. Bates S (2010) Progress towards personalized medicine. Drug Discov Today 15:115-120.
9. Beckonert O, Keun HC, Ebbels TMD, Bundy J, Holmes E, Lindon JC, and Nicholson JK (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2:2692-2703.
10. Björkholm B, Bok CM, Lundin A, Rafter J, Hibberd ML, and Pettersson S (2009) Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS ONE 4:e6958.
11. Blaut M, Collins MD, Welling GW, Doré J, van Loo J, and de Vos W (2002) Molecular biological methods for studying the gut microbiota: the EU human gut flora project. Br J Nutr 87 (Suppl 2):S203-S211.
12. Bosch TM, Meijerman I, Beijnen JH, and Schellens JH (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253-285.
13. Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, Bjorndahl TC, Krishnamurthy R, Saleem F, and Liu P, et al. (2013) The human urine metabolome. PLoS ONE 8:e73076.
14. Bruce SJ, Tavazzi I, Parisod V, Rezzi S, Kochhar S, and Guy PA (2009) Investigation of human blood plasma sample preparation for performing metabolomics using ultrahigh performance liquid chromatography/mass spectrometry. Anal Chem 81:3285-3296.
15. Brugère JF, Mihajlovski A, Missaoui M, and Peyret P (2009) Tools for stools: the challenge of assessing human intestinal microbiota using molecular diagnostics. Expert Rev Mol Diagn 9: 353-365.
16. Caldwell J and Hawksworth GM (1973) The demethylation of methamphetamine by intestinal microflora. J Pharm Pharmacol 25:422-424.
17. Carmody RN and Turnbaugh PJ (2014) Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest 124:4173-4181.
18. Chakravorty S, Helb D, Burday M, Connell N, and Alland D (2007) A detailed analysis of 16S ribosomal RNA gene segments for the diagnosis of pathogenic bacteria. J Microbiol Methods 69:330-339.
19. Chan ECY, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, Nicholson JK, and Keun HC (2009) Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 8:352-361.
20. Chan ECY, Pasikanti KK, and Nicholson JK (2011) Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. Nat Protoc 6:1483-1499.
21. Chan IS and Ginsburg GS (2011) Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet 12:217-244.
22. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, and Lennard-Jones JE (1983) Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci 28:609-615.
23. Claus SP, Ellero SL, Berger B, Krause L, Bruttin A, Molina J, Paris A, Want EJ, de Waziers I, and Cloarec O, et al. (2011) Colonization-induced host-gut microbial metabolic interaction. MBio 2:e00271-10.
24. Claus SP, Tsang TM, Wang Y, Cloarec O, Skordi E, Martin FP, Rezzi S, Ross A, Kochhar S, and Holmes E, et al. (2008) Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol Syst Biol 4:219.
25. Clayton TA, Baker D, Lindon JC, Everett JR, and Nicholson JK (2009) Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 106:14728-14733.
26. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, and Walley RJ, et al. (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073-1077.
27. Coates M, Drasar B, Mallett A, Rowland I, and Rowland I (1988) Methodological considerations for the study of bacterial metabolism, in Role of the Gut Flora in Toxicity and Cancer, pp 1-21, Academic Press, San Diego, CA.
28. Dave M, Higgins PD, Middha S, and Rioux KP (2012) The human gut microbiome: current knowledge, challenges, and future directions. Transl Res 160:246-257.
29. Dawson PA (2011) Role of the intestinal bile acid transporters in bile acid and drug disposition. Handbook Exp Pharmacol 201:169-203.
30. Dearing MD, Foley WJ, and McLean S (2005) The influence of plant secondary metabolites on the nutritional ecology of herbivorous terrestrial vertebrates. Annu Rev Ecol Evol Syst 36:169-189.
31. Deloménie C, Fouix S, Longuemaux S, Brahimi N, Bizet C, Picard B, Denamur E, and Dupret JM (2001) Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol 183: 3417-3427.
32. Doern GV (2000) Detection of selected fastidious bacteria. Clin Infect Dis 30:166-173.
33. Duggan DE, Hooke KF, Noll RM, and Kwan KC (1975) Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol 24:1749-1754.
34. Dull BJ, Salata K, and Goldman P (1987) Role of the intestinal flora in the acetylation of sulfasalazine metabolites. Biochem Pharmacol 36:3772-3774.
35. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, Brown M, Knowles JD, Halsall A, and Haselden JN, et al.; Human Serum Metabolome (HUSERMET) Consortium (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 6: 1060-1083.
36. Elmer GW and Remmel RP (1984) Role of the intestinal microflora in clonazepam metabolism in the rat. Xenobiotica 14:829-840.
37. Enot DP, Haas B, and Weinberger KM (2011) Bioinformatics for mass spectrometry-based metabolomics, in Bioinformatics for Omics Data: Methods and Protocols (Mayer B ed) pp 351-375, Humana Press, New York.
38. Fraher MH, O'Toole PW, and Quigley EM (2012) Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 9:312-322.
39. Gingell R, Bridges JW, and Williams RT (1971) The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. Xenobiotica 1:143-156.
40. Ginsburg GS and McCarthy JJ (2001) Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 19:491-496.
41. Goldin BR, Peppercorn MA, and Goldman P (1973) Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J Pharmacol Exp Ther 186:160-166.
42. Goldman P (1978) Biochemical pharmacology of the intestinal flora. Annu Rev Pharmacol Toxicol 18:523-539.
43. Guengerich FP (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 8:E101-E111.
44. Guinane CM and Cotter PD (2013) Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol 6:295-308.
45. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, and Turnbaugh PJ (2013) Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341:295-298.
46. Haiser HJ and Turnbaugh PJ (2012) Is it time for a metagenomic basis of therapeutics? Science 336:1253-1255.
47. Haiser HJ and Turnbaugh PJ (2013) Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res 69:21-31.
48. Hamburg MA and Collins FS (2010) The path to personalized medicine. N Engl J Med 363: 301-304.
49. Han J, Antunes LCM, Finlay BB, and Borchers CH (2010) Metabolomics: towards understanding host-microbe interactions. Future Microbiol 5:153-161.
50. Hao WL and Lee YK (2004) Microflora of the gastrointestinal tract: a review. Methods Mol Biol 268:491-502.
51. Holmes E, Kinross J, Gibson GR, Burcelin R, Jia W, Pettersson S, and Nicholson JK (2012) Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med 4:137rv136.
52. Holt R (1967) The bacterial degradation of chloramphenicol. Lancet 1:1259-1260.
53. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen DT, and Austin CP (2011) The NCGC Pharmaceutical Collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 3:80ps16.
54. Hylemon PB (1985) Metabolism of bile acids in intestinal microflora, in New Comprehensive Biochemistry (Danielsson H and Sjövall J eds) pp 331-343, Elsevier, Amsterdam, The Netherlands.
55. Ieiri I, Takane H, Hirota T, Otsubo K, and Higuchi S (2006) Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin Drug Metab Toxicol 2:651-674.
56. Ingelman-Sundberg M, Oscarson M, and McLellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 20: 342-349.
57. Iyanagi T (2007) Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. Int Rev Cytol 260:35-112.
58. Jia W, Li H, Zhao L, and Nicholson JK (2008) Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov 7:123-129.
59. Kaal E and Janssen HG (2008) Extending the molecular application range of gas chromatography. J Chromatogr A 1184:43-60.
60. Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng Z-B, Wiest MM, Nguyen UT, Wojnoonski K, Watkins SM, Trupp M, and Krauss RM (2011) Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 6:e25482.
61. Kang DW, Park JG, Ilhan ZE, Wallstrom G, Labaer J, Adams JB, and Krajmalnik-Brown R (2013) Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS ONE 8:e68322.
62. Karasov WH (1989) Nutritional bottleneck in a herbivore, the desert woodrat (Neotoma lepida). Physiol Zool 62:1351-1382.
63. Kerb R (2006) Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234:4-33.
64. Khoury MJ, Rich EC, Randhawa G, Teutsch SM, and Niederhuber J (2009) Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine. Genet Med 11:707-711.
65. Kitamura S, Sugihara K, Kuwasako M, and Tatsumi K (1997) The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol 49:253-256.
66. Koch RL, Beaulieu BB, Jr, and Goldman P (1980) Role of the intestinal flora in the metabolism of misonidazole. Biochem Pharmacol 29:3281-3284.
67. Koch RL, Chrystal EJ, Beaulieu BB, Jr, and Goldman P (1979) Acetamide - a metabolite of metronidazole formed by the intestinal flora. Biochem Pharmacol 28:3611-3615.
68. Kohl KD, Weiss RB, Cox J, Dale C, and Dearing MD (2014) Gut microbes of mammalian herbivores facilitate intake of plant toxins. Ecol Lett 17:1238-1246.
69. Kostic AD, Xavier RJ, and Gevers D (2014) The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146:1489-1499.
70. Kuczynski J, Lauber CL, Walters WA, Parfrey LW, Clemente JC, Gevers D, and Knight R (2012) Experimental and analytical tools for studying the human microbiome. Nat Rev Genet 13: 47-58.
71. Kumar V, Abbas AK, Aster JC, and Robbins SL (2013) Robbins Basic Pathology, Elsevier/Saunders, Philadelphia, PA.
72. Lambert JD, Zhao D, Meyers RO, Kuester RK, Timmermann BN, and Dorr RT (2002) Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse. Toxicon 40:1701-1708.
73. Leckband SG, Kelsoe JR, Dunnenberger HM, George AL, Jr, Tran E, Berger R, Müller DJ, Whirl-Carrillo M, Caudle KE, and Pirmohamed M Clinical Pharmacogenetics Implementation Consortium (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 94:324-328.
74. Lederberg J (2000) Infectious history. Science 288:287-293.
75. Li H and Jia W (2013) Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther 94:574-581.
76. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, Zhang Y, Shen J, Pang X, and Zhang M, et al. (2008) Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 105:2117-2122.
77. Li T and Chiang JY (2013) Nuclear receptors in bile acid metabolism. Drug Metab Rev 45: 145-155.
78. Lindenbaum J, Rund DG, Butler VP, Jr, Tse-Eng D, and Saha JR (1981) Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 305:789-794.
79. Lindon JC, Holmes E, and Nicholson JK (2007) Metabonomics in pharmaceutical R&D. FEBS J 274:1140-1151.
80. Lindon JC, Keun HC, Ebbels TMD, Pearce JMT, Holmes E, and Nicholson JK (2005) The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6:691-699.
81. Lindon JC, Nicholson JK, Holmes E, Antti H, Bollard ME, Keun H, Beckonert O, Ebbels TM, Reily MD, and Robertson D, et al. (2003) Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol Appl Pharmacol 187:137-146.
82. LoGuidice A, Wallace BD, Bendel L, Redinbo MR, and Boelsterli UA (2012) Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther 341:447-454.
83. Lu K, Abo RP, Schlieper KA, Graffam ME, Levine S, Wishnok JS, Swenberg JA, Tannenbaum SR, and Fox JG (2014) Arsenic exposure perturbs the gut microbiome and its metabolic profile in mice: an integrated metagenomics and metabolomics analysis. Environ Health Perspect 122: 284-291.
84. Lum PY, Derry JMJ, and Schadt EE (2009) Integrative genomics and drug development. Pharmacogenomics 10:203-212.
85. Macdonald IA, Bokkenheuser VD, Winter J, McLernon AM, and Mosbach EH (1983) Degradation of steroids in the human gut. J Lipid Res 24:675-700.
86. Mal M, Koh PK, Cheah PY, and Chan ECY (2009) Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. Rapid Commun Mass Spectrom 23:487-494.
87. Mal M, Koh PK, Cheah PY, and Chan ECY (2012) Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Anal Bioanal Chem 403:483-493.
88. Mancinelli L, Cronin M, and Sadée W (2000) Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci 2:E4.
89. Mandal R, Guo AC, Chaudhary KK, Liu P, Yallou FS, Dong E, Aziat F, and Wishart DS (2012) Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. Genome Med 4:38.
90. Manichanh C, Reeder J, Gibert P, Varela E, Llopis M, Antolin M, Guigo R, Knight R, and Guarner F (2010) Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. Genome Res 20:1411-1419.
91. Martin FP, Dumas ME, Wang Y, Legido-Quigley C, Yap IK, Tang H, Zirah S, Murphy GM, Cloarec O, and Lindon JC, et al. (2007) A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol 3:112.
92. Martin FP, Sprenger N, Yap IK, Wang Y, Bibiloni R, Rochat F, Rezzi S, Cherbut C, Kochhar S, and Lindon JC, et al. (2009) Panorganismal gut microbiome-host metabolic crosstalk. J Proteome Res 8:2090-2105.
93. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182-2194.
94. Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Oyaizu H, and Tanaka R (2002) Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. Appl Environ Microbiol 68:5445-5451.
95. Matsumoto M and Benno Y (2007) The relationship between microbiota and polyamine concentration in the human intestine: a pilot study. Microbiol Immunol 51:25-35.
96. Maurice CF, Haiser HJ, and Turnbaugh PJ (2013) Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152:39-50.
97. Meuldermans W, Hendrickx J, Mannens G, Lavrijsen K, Janssen C, Bracke J, Le Jeune L, Lauwers W, and Heykants J (1994) The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos 22:129-138.
98. Miura H, Horiguchi M, and Matsumoto T (1980) Nutritional interdependence among rumen bacteria, Bacteroides amylophilus, Megasphaera elsdenii, and Ruminococcus albus. Appl Environ Microbiol 40:294-300.
99. Molina DK and DiMaio VJ (2012) Normal organ weights in men: part II-the brain, lungs, liver, spleen, and kidneys. Am J Forensic Med Pathol 33:368-372.
100. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, and Snapper SB, et al. (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79.
101. Nebert DW, Jorge-Nebert L, and Vesell ES (2003) Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am J Pharmacogenomics 3: 361-370.
102. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, and Pettersson S (2012) Host-gut microbiota metabolic interactions. Science 336:1262-1267.
103. Nicholson JK, Holmes E, and Wilson ID (2005) Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 3:431-438.
104. Nicholson JK, Lindon JC, and Holmes E (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29:1181-1189.
105. Nicholson JK and Wilson ID (2003) Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov 2:668-676.
106. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
107. Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, Ryals JA, Beebe KD, and Guo L (2009) Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol 37:521-535.
108. Okuda H, Ogura K, Kato A, Takubo H, and Watabe T (1998) A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluoro-uracil prodrugs. J Pharmacol Exp Ther 287:791-799.
109. Oleson L and Court MH (2008) Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases. J Pharm Pharmacol 60:1175-1182.
110. Park BK and Breckenridge AM (1981) Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 6:1-24.
111. Park BK, Kitteringham NR, Pirmohamed M, and Tucker GT (1996) Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 41:477-491.
112. Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu QH, Chiong E, and Chan ECY (2010a) Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res 9:2988-2995.
113. Pasikanti KK, Ho PC, and Chan EC (2008) Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 871: 202-211.
114. Pasikanti KK, Norasmara J, Cai S, Mahendran R, Esuvaranathan K, Ho PC, and Chan ECY (2010b) Metabolic footprinting of tumorigenic and nontumorigenic uroepithelial cells using two-dimensional gas chromatography time-of-flight mass spectrometry. Anal Bioanal Chem 398:1285-1293.
115. Peppercorn MA and Goldman P (1972) The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 181:555-562.
116. Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, and Deal C, et al.; NIH HMP Working Group (2009) The NIH Human Microbiome Project. Genome Res 19:2317-2323.
117. Polz MF and Cavanaugh CM (1998) Bias in template-to-product ratios in multitemplate PCR. Appl Environ Microbiol 64:3724-3730.
118. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789-802.
119. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, and Gautam B, et al. (2011) The human serum metabolome. PLoS ONE 6:e16957.
120. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, and Yamada T, et al.; MetaHIT Consortium (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59-65.
121. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, and Shen D, et al. (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55-60.
122. Quinones MP and Kaddurah-Daouk R (2009) Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 35:165-176.
123. Rafii F, Sutherland JB, Hansen EB, Jr, and Cerniglia CE (1997) Reduction of nitrazepam by Clostridium leptum, a nitroreductase-producing bacterium isolated from the human intestinal tract. Clin Infect Dis 25 (Suppl 2):S121-S122.
124. Rinttilä T, Kassinen A, Malinen E, Krogius L, and Palva A (2004) Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 97:1166-1177.
125. Roberts AB, Wallace BD, Venkatesh MK, Mani S, and Redinbo MR (2013) Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol 84: 208-217.
126. Roberts MS, Magnusson BM, Burczynski FJ, and Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790.
127. Robertson LW, Chandrasekaran A, Reuning RH, Hui J, and Rawal BD (1986) Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum. Appl Environ Microbiol 51: 1300-1303.
128. Rod TO and Midtvedt T (1977) Origin of intestinal beta-glucuronidase in germfree, monocontaminated and conventional rats. Acta Pathol Microbiol Scand [B] 85:271-276.
129. Rohlke F and Stollman N (2012) Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther Adv Gastroenterol 5:403-420.
130. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, and Eckhardt SG, et al. (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135.
131. Rowland IR (1988) Interactions of the gut microflora and the host in toxicology. Toxicol Pathol 16:147-153.
132. Saha JR, Butler VP, Jr, Neu HC, and Lindenbaum J (1983) Digoxin-inactivating bacteria: identification in human gut flora. Science 220:325-327.
133. Sahota SS, Bramley PM, and Menzies IS (1982) The fermentation of lactulose by colonic bacteria. J Gen Microbiol 128:319-325.
134. Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, and Boelsterli UA (2014) Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica 44:28-35.
135. Savage DC (1977) Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 31: 107-133.
136. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Oresic M, and Bäckhed F (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17: 225-235.
137. Scheline RR (1968) Drug metabolism by intestinal microorganisms. J Pharm Sci 57:2021-2037.
138. Scheline RR (1973) Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 25:451-523.
139. Shenfield GM (2004) Genetic polymorphisms, drug metabolism and drug concentrations. Clin Biochem Rev 25:203-206.
140. Shu YZ, Kingston DG, Van Tassell RL, and Wilkins TD (1991) Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria. Xenobiotica 21:737-750.
141. Smith GE and Griffiths LA (1974) Metabolism of N-acylated and O-alkylated drugs by the intestinal microflora during anaerobic incubation in vitro. Xenobiotica 4:477-487.
142. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, and Basit AW (2008) The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 363:1-25.
143. Spatzenegger M and Jaeger W (1995) Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27:397-417.
144. Stams AJ (1994) Metabolic interactions between anaerobic bacteria in methanogenic environments. Antonie van Leeuwenhoek 66:271-294.
145. Strong HA, Renwick AG, George CF, Liu YF, and Hill MJ (1987) The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Xenobiotica 17:685-696.
146. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, and Holmes E (2011) Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci USA 108 (Suppl 1):4523-4530.
147. Sweeney TE and Morton JM (2013) The human gut microbiome: a review of the effect of obesity and surgically induced weight loss. JAMA Surg 148:563-569.
148. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, and Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752-3757.
149. Takeno S and Sakai T (1991) Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction. Teratology 44:209-214.
150. Toda T, Saito N, Ikarashi N, Ito K, Yamamoto M, Ishige A, Watanabe K, and Sugiyama K (2009) Intestinal flora induces the expression of Cyp3a in the mouse liver. Xenobiotica 39:323-334.
151. Toivanen P, Vaahtovuo J, and Eerola E (2001) Influence of major histocompatibility complex on bacterial composition of fecal flora. Infect Immun 69:2372-2377.
152. Tomalik-Scharte D, Lazar A, Fuhr U, and Kirchheiner J (2008) The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8:4-15.
153. Tozaki H, Emi Y, Horisaka E, Fujita T, Yamamoto A, and Muranishi S (1997) Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: implications in peptide delivery to the colon. J Pharm Pharmacol 49:164-168.
154. Tuohy KM and McCartney AL (2006) Molecular microbial ecology of the human gut, in Prebiotics: Development & Application (Rastall B and Gibson G eds) pp 135-155, John Wiley & Sons, Ltd., Hoboken, NJ.
155. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, and Affourtit JP, et al. (2009) A core gut microbiome in obese and lean twins. Nature 457:480-484.
156. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, and Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027-1031.
157. Verschuren JJW, Trompet S, Wessels JAM, Guchelaar HJ, de Maat MPM, Simoons ML, and Jukema JW (2012) A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J 33:165-175.
158. Volp RF and Lage GL (1978) The fate of a major biliary metabolite of digitoxin in the rat intestine. Drug Metab Dispos 6:418-424.
159. Wadworth AN and Fitton A (1991) Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs 41:647-664.
160. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, and Mani S, et al. (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330:831-835.
161. Walsh CT and Levine RR (1975) Studies of the enterohepatic circulation of morphine in the rat. J Pharmacol Exp Ther 195:303-310.
162. Want EJ, Masson P, Michopoulos F, Wilson ID, Theodoridis G, Plumb RS, Shockcor J, Loftus N, Holmes E, and Nicholson JK (2013) Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc 8:17-32.
163. Watanabe K, Yamashita S, Furuno K, Kawasaki H, and Gomita Y (1995) Metabolism of omeprazole by gut flora in rats. J Pharm Sci 84:516-517.
164. Weinstock GM (2012) Genomic approaches to studying the human microbiota. Nature 489: 250-256.
165. Weiss RH and Kim K (2012) Metabolomics in the study of kidney diseases. Nat Rev Nephrol 8: 22-33.
166. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, and Siuzdak G (2009) Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 106:3698-3703.
167. Wilson ID and Nicholson JK (2009) The role of gut microbiota in drug response. Curr Pharm Des 15:1519-1523.
168. Wishart DS (2009) Computational approaches to metabolomics, in Bioinformatics Methods in Clinical Research (Matthiesen R ed) pp 283-313, Humana Press, New York.
169. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, and Dong E, et al. (2013) HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res 41:D801-D807.
170. Wishart DS, Lewis MJ, Morrissey JA, Flegel MD, Jeroncic K, Xiong Y, Cheng D, Eisner R, Gautam B, and Tzur D, et al. (2008) The human cerebrospinal fluid metabolome. J Chromatogr B Analyt Technol Biomed Life Sci 871:164-173.
171. Woodcock J (2007) The prospects for "personalized medicine" in drug development and drug therapy. Clin Pharmacol Ther 81:164-169.
172. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
173. Yap IK, Li JV, Saric J, Martin FP, Davies H, Wang Y, Wilson ID, Nicholson JK, Utzinger J, and Marchesi JR, et al. (2008) Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res 7: 3718-3728.
174. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, Hidalgo G, Baldassano RN, and Anokhin AP, et al. (2012) Human gut microbiome viewed across age and geography. Nature 486:222-227.
175. Yip LY and Chan ECY (2013) Gas chromatography/mass spectrometry-based metabonomics, in Proteomic and Metabolomic Approaches to Biomarker Discovery (Issaq HJ and Veenstra TD eds) pp 131-144, Academic Press, Boston.
176. Yoo DH, Kim IS, Van Le TK, Jung IH, Yoo HH, and Kim DH (2014) Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos 42:1508-1513.
177. Yoshida M, Hatano N, Nishiumi S, Irino Y, Izumi Y, Takenawa T, and Azuma T (2012) Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatographymass spectrometry. J Gastroenterol 47:9-20.
178. Zgoda-Pols JR, Chowdhury S, Wirth M, Milburn MV, Alexander DC, and Alton KB (2011) Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol 255:48-56.
179. Zhao Y, Wu J, Li JV, Zhou NY, Tang H, and Wang Y (2013) Gut microbiota composition modifies fecal metabolic profiles in mice. J Proteome Res 12:2987-2999.
180. Zheng X, Xie G, Zhao A, Zhao L, Yao C, Chiu NH, Zhou Z, Bao Y, Jia W, and Nicholson JK, et al. (2011) The footprints of gut microbial-mammalian co-metabolism. J Proteome Res 10: 5512-5522.
181. Zhou SF, Di YM, Chan E, Du YM, Chow VDW, Xue CC, Lai X, Wang JC, Li CG, and Tian M, et al. (2008) Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 9:738-784.